|
EP2796468A2
(en)
|
2001-01-05 |
2014-10-29 |
Pfizer Inc |
Antibodies to insulin-like growth factor I receptor
|
|
MY143582A
(en)
|
2001-06-26 |
2011-05-31 |
Amgent Fremont Inc |
Antibodies to opgl
|
|
AU2013204100A1
(en)
*
|
2001-06-26 |
2013-05-09 |
Amgen Fremont Inc. |
Antibodies to OPGL
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
|
US7553485B2
(en)
|
2002-01-18 |
2009-06-30 |
Pierre Fabre Medicament |
Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
|
|
EP1806364B1
(fr)
*
|
2002-01-18 |
2013-07-31 |
Pierre Fabre Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
FR2834991B1
(fr)
*
|
2002-01-18 |
2004-12-31 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
FR2834900B1
(fr)
*
|
2002-01-18 |
2005-07-01 |
Pf Medicament |
Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
|
|
FR2834990A1
(fr)
*
|
2002-01-18 |
2003-07-25 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
US6936427B2
(en)
*
|
2002-02-08 |
2005-08-30 |
Trellis Bioscience, Inc. |
Real time detection of intermolecular interaction
|
|
AU2003237864B2
(en)
*
|
2002-05-15 |
2008-12-18 |
California Pacific Medical Center |
Delivery of nucleic acid-like compounds
|
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US7538195B2
(en)
*
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
AU2004303792A1
(en)
*
|
2003-12-08 |
2005-07-07 |
Immunogen, Inc. |
Anti-IGF-I receptor antibody
|
|
US7456260B2
(en)
|
2002-06-17 |
2008-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized antibody
|
|
AU2003275240A1
(en)
*
|
2002-09-24 |
2004-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for soluble cpg15
|
|
CA2514231A1
(en)
*
|
2003-02-13 |
2004-08-26 |
Pfizer Products Inc. |
Uses of anti-insulin-like growth factor i receptor antibodies
|
|
CA2518980A1
(en)
*
|
2003-03-14 |
2004-09-30 |
Pharmacia Corporation |
Antibodies to igf-i receptor for the treatment of cancers
|
|
CN100378127C
(zh)
*
|
2003-04-02 |
2008-04-02 |
霍夫曼-拉罗奇有限公司 |
针对胰岛素样生长因子i受体的抗体及其应用
|
|
US7378503B2
(en)
|
2003-04-02 |
2008-05-27 |
Hoffmann-La Roche Inc. |
Antibodies against insulin-like growth factor 1 receptor and uses thereof
|
|
US7310537B2
(en)
*
|
2003-04-25 |
2007-12-18 |
Nokia Corporation |
Communication on multiple beams between stations
|
|
WO2005016970A2
(en)
|
2003-05-01 |
2005-02-24 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
ES2338105T3
(es)
*
|
2003-05-14 |
2010-05-04 |
Kenta Biotech Ag |
Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa.
|
|
US7579157B2
(en)
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
DE602004029581D1
(de)
*
|
2003-08-13 |
2010-11-25 |
Pfizer Prod Inc |
Modifizierte humane igf-1r antikörper
|
|
US7498415B2
(en)
*
|
2003-09-24 |
2009-03-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Recombinant antibody against human insulin-like growth factor
|
|
US20050187175A1
(en)
*
|
2003-09-30 |
2005-08-25 |
Elly Nedivi |
Methods and compositions for CPG15-2
|
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
JP2007536254A
(ja)
*
|
2004-05-05 |
2007-12-13 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
|
WO2006008639A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
|
FR2873699B1
(fr)
*
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
MX2007006640A
(es)
*
|
2004-12-03 |
2007-06-19 |
Schering Corp |
Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
EP3300739A3
(en)
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
AU2006236637B2
(en)
*
|
2005-04-15 |
2012-09-06 |
Merck Sharp & Dohme Corp. |
Methods and compositions for treating or preventing cancer
|
|
KR101203328B1
(ko)
|
2005-04-26 |
2012-11-20 |
화이자 인코포레이티드 |
Ｐ-카드헤린 항체
|
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
|
ES2776657T3
(es)
*
|
2005-06-14 |
2020-07-31 |
Amgen Inc |
Formulaciones de proteínas autotamponantes
|
|
CN101287761A
(zh)
*
|
2005-06-15 |
2008-10-15 |
先灵公司 |
抗-igf1r抗体制剂
|
|
PT2100618E
(pt)
|
2005-06-17 |
2014-04-07 |
Philadelphia Health & Educatio |
Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
|
|
WO2007000328A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
|
|
FR2888850B1
(fr)
*
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
HN2006031275A
(es)
|
2005-09-07 |
2010-10-29 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
|
CN100445300C
(zh)
*
|
2005-09-30 |
2008-12-24 |
李玉新 |
Glp-1融合蛋白及其制备方法和医药用途
|
|
EP1957541A2
(en)
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
AR060017A1
(es)
|
2006-01-13 |
2008-05-21 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos de dickkopf -1
|
|
EP3360965A1
(en)
|
2006-01-20 |
2018-08-15 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
AU2007212447B2
(en)
|
2006-02-03 |
2013-02-21 |
Imclone Llc |
IGF-IR antagonists as adjuvants for treatment of prostate cancer
|
|
WO2007095113A2
(en)
*
|
2006-02-10 |
2007-08-23 |
Massachusetts Institute Of Technology |
Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
|
|
AU2007229554A1
(en)
*
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-IGF-1R human monoclonal antibody formulation
|
|
EA200802061A1
(ru)
|
2006-03-28 |
2009-04-28 |
Байоджен Айдек Эмэй Инк. |
Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
EP3266867A1
(en)
|
2006-04-14 |
2018-01-10 |
Cell Signaling Technology, Inc. |
Gene defects and mutant alk kinase in human solid tumors
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
|
WO2008079849A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
|
GB0702888D0
(en)
*
|
2007-02-14 |
2007-03-28 |
Glaxo Group Ltd |
Novel Antibodies
|
|
KR20090114449A
(ko)
*
|
2007-02-14 |
2009-11-03 |
글락소 그룹 리미티드 |
Ｉｇｆ-ⅰｒ에 대한 항체
|
|
US20100323373A1
(en)
*
|
2007-02-27 |
2010-12-23 |
Stefan Evers |
Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor
|
|
WO2008108986A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Amgen Inc. |
Methods and compositions for treating tumor diseases
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
US8492328B2
(en)
|
2007-05-17 |
2013-07-23 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
WO2009032145A1
(en)
*
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Anti-igf-1r antibodies and uses thereof
|
|
US20090130105A1
(en)
*
|
2007-08-28 |
2009-05-21 |
Biogen Idec Ma Inc. |
Compositions that bind multiple epitopes of igf-1r
|
|
EP2197421A1
(en)
*
|
2007-08-31 |
2010-06-23 |
Amgen, Inc |
Solid-state protein formulation
|
|
WO2009043049A2
(en)
*
|
2007-09-27 |
2009-04-02 |
Amgen Inc. |
Pharmaceutical formulations
|
|
EP2203558B1
(en)
|
2007-10-18 |
2016-05-04 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
|
HUE032735T2
(en)
|
2007-12-14 |
2017-10-30 |
Bristol Myers Squibb Co |
Binding molecules for the human OX40 receptor
|
|
CA2709029A1
(en)
|
2007-12-21 |
2009-07-02 |
Bianca Eser |
Stability testing of antibodies
|
|
CA2718918A1
(en)
*
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
AR072000A1
(es)
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
|
|
BRPI0915448A2
(pt)
|
2008-07-08 |
2015-11-10 |
Abbott Lab |
imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
|
|
ES2378513T3
(es)
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
|
AR074726A1
(es)
|
2008-12-12 |
2011-02-09 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf (factor de crecimiento insulinico)
|
|
DK2881402T3
(en)
|
2009-02-12 |
2017-08-28 |
Cell Signaling Technology Inc |
Mutant ROS expression in human liver cancer
|
|
ES2738700T3
(es)
|
2009-02-13 |
2020-01-24 |
Immunomedics Inc |
Inmunoconjugados con un enlace escindible intracelularmente
|
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
|
EP2236139A1
(en)
|
2009-03-31 |
2010-10-06 |
F. Hoffmann-La Roche AG |
Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
|
|
CN102481361B
(zh)
|
2009-04-16 |
2014-10-22 |
默沙东公司 |
用于治疗癌症的组合物和方法
|
|
EA027071B1
(ru)
*
|
2009-04-27 |
2017-06-30 |
Новартис Аг |
АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CN102638971B
(zh)
|
2009-07-08 |
2015-10-07 |
科马布有限公司 |
动物模型及治疗分子
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX344382B
(es)
|
2009-10-23 |
2016-12-14 |
Amgen Inc * |
Adaptador de vial y sistema.
|
|
EP4406615A3
(en)
|
2009-10-26 |
2024-12-11 |
F. Hoffmann-La Roche AG |
Method for the production of a glycosylated immunoglobulin
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2011053779A2
(en)
|
2009-10-30 |
2011-05-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US10143186B2
(en)
|
2010-02-08 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
|
JP6200806B2
(ja)
|
2010-05-21 |
2017-09-20 |
メリマック ファーマシューティカルズ インコーポレーティッド |
二重特異的融合タンパク質
|
|
HUE026173T2
(en)
|
2010-06-07 |
2016-05-30 |
Amgen Inc |
pharmaceutical Pump
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
PE20130643A1
(es)
|
2010-07-12 |
2013-06-07 |
Covx Technologies Ireland Ltd |
Conjugados de anticuerpos multifuncionales
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
|
SG187938A1
(en)
|
2010-08-26 |
2013-04-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
CN103221428B
(zh)
|
2010-09-09 |
2016-02-10 |
辉瑞公司 |
4-1bb结合分子
|
|
JP6073230B2
(ja)
*
|
2010-09-28 |
2017-02-01 |
ノノ インコーポレイテッド |
Ｎｄ２ペプチドおよび神経疾患の治療方法
|
|
EP2640750A1
(en)
*
|
2010-11-16 |
2013-09-25 |
Boehringer Ingelheim International GmbH |
Agents and methods for treating diseases that correlate with bcma expression
|
|
EP2643694B1
(en)
|
2010-11-24 |
2018-01-03 |
Litron Laboratories Ltd. |
Rapid in vivo gene mutation assay based on the pig-a gene
|
|
US20140037642A1
(en)
|
2011-02-02 |
2014-02-06 |
Amgen Inc. |
Methods and compositions relating to inhibition of igf-1r
|
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
|
US9402916B2
(en)
|
2011-03-17 |
2016-08-02 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
ME03353B
(me)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
AU2012236573B2
(en)
|
2011-03-31 |
2016-06-02 |
Amgen Inc. |
Vial adapter and system
|
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
KR20140138353A
(ko)
*
|
2011-04-19 |
2014-12-03 |
메리맥 파마슈티컬즈, 인크. |
단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
|
|
TR201905991T4
(tr)
|
2011-04-20 |
2019-05-21 |
Amgen Inc |
Oto enjektör aparatı.
|
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
|
HRP20192255T1
(hr)
|
2011-08-05 |
2020-03-06 |
Regeneron Pharmaceuticals, Inc. |
Humanizirani miševi s univerzalnim lakim lancem
|
|
MX2014002289A
(es)
|
2011-08-26 |
2015-03-20 |
Merrimack Pharmaceuticals Inc |
Anticuerpos fc especificos en tandem.
|
|
BR112014006390A2
(pt)
*
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
US20140309229A1
(en)
|
2011-10-13 |
2014-10-16 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
EP3045188B1
(en)
|
2011-10-14 |
2020-12-23 |
Amgen Inc. |
Injector and method of assembly
|
|
WO2013060872A1
(en)
*
|
2011-10-27 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Anticancer combination therapy
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
CA2852127C
(en)
|
2011-11-11 |
2020-10-27 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR101470700B1
(ko)
*
|
2011-11-25 |
2014-12-12 |
서울대학교산학협력단 |
표적 항암제의 내성 극복 방법
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9997847B2
(en)
|
2011-12-27 |
2018-06-12 |
Perfectvision Manufacturing, Inc. |
Coaxial Connector with grommet biasing for enhanced continuity
|
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
|
EP2631653A1
(en)
|
2012-02-24 |
2013-08-28 |
Charité - Universitätsmedizin Berlin |
Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
DK2838998T3
(en)
|
2012-04-18 |
2018-01-15 |
Cell Signaling Technology Inc |
EGFR AND ROS1 IN CANCER
|
|
CA2871711A1
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
EP2863947B1
(en)
|
2012-06-21 |
2018-03-07 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind igf1r
|
|
WO2014014821A1
(en)
|
2012-07-19 |
2014-01-23 |
Redwood Biosciences, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
WO2014055877A1
(en)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
EP2922590B1
(en)
|
2012-11-21 |
2020-02-05 |
Amgen Inc. |
Drug delivery device
|
|
KR102196374B1
(ko)
|
2012-11-29 |
2020-12-31 |
케모센트릭스, 인크. |
Cxcr7 길항제
|
|
AU2013360335B2
(en)
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
MX2015011712A
(es)
|
2013-03-06 |
2016-04-04 |
Merrimack Pharmaceuticals Inc |
Anticerpos biespecificos fc en fila anti-c-met.
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
|
|
US10092703B2
(en)
|
2013-03-15 |
2018-10-09 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
|
SG11201507417RA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Body contour adaptable autoinjector device
|
|
TWI614041B
(zh)
|
2013-03-15 |
2018-02-11 |
安美基公司 |
用於注射器之匣盒
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP2976117B1
(en)
|
2013-03-22 |
2020-12-30 |
Amgen Inc. |
Injector and method of assembly
|
|
FI3677591T3
(fi)
|
2013-04-29 |
2023-04-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
DK3007704T3
(da)
*
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
|
TW201605896A
(zh)
*
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015035215A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
ES2993142T3
(en)
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
CA2920894C
(en)
|
2013-10-24 |
2023-03-14 |
Amgen Inc. |
Injector and method of assembly
|
|
EP3957345B1
(en)
|
2013-10-24 |
2025-12-10 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
EP3094339B1
(en)
|
2014-01-12 |
2019-12-11 |
IGF Oncology, LLC |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
EP3107577B1
(en)
|
2014-02-21 |
2024-03-20 |
IBC Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
|
SG10201808225TA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Non-human animals that make single domain binding proteins
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
MX388536B
(es)
|
2014-05-07 |
2025-03-20 |
Amgen Inc |
Autoinyector con elementos reductores del shock.
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
CN106470717B
(zh)
|
2014-06-03 |
2020-09-11 |
安姆根有限公司 |
药物递送系统和使用方法
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
CA2961774C
(en)
|
2014-10-07 |
2023-05-23 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
AU2015332557B2
(en)
|
2014-10-14 |
2020-05-14 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
RU2711930C2
(ru)
|
2014-11-19 |
2020-01-23 |
Иммуноджен, Инк. |
Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
ES2785311T3
(es)
|
2014-12-19 |
2020-10-06 |
Amgen Inc |
Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
|
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
CA3069716C
(en)
|
2015-02-17 |
2021-11-09 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
|
TW201632559A
(zh)
*
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
EP3261690B1
(en)
|
2015-02-27 |
2021-12-15 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
|
HK1250038A1
(zh)
|
2015-03-19 |
2018-11-23 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
US9797907B2
(en)
|
2015-04-22 |
2017-10-24 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
CN115960249A
(zh)
|
2015-10-02 |
2023-04-14 |
银溪制药股份有限公司 |
用于组织修复的双特异性治疗性蛋白质
|
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
|
ES2908470T3
(es)
|
2015-11-09 |
2022-04-29 |
Scherer Technologies Llc R P |
Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
|
|
WO2017100501A1
(en)
|
2015-12-09 |
2017-06-15 |
Amgen Inc. |
Auto-injector with signaling cap
|
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
AU2017213858A1
(en)
|
2016-02-05 |
2018-08-16 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
HRP20241557T1
(hr)
|
2016-03-10 |
2025-05-23 |
Acceleron Pharma Inc. |
Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
|
|
WO2017160799A1
(en)
|
2016-03-15 |
2017-09-21 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
AU2017263558B2
(en)
|
2016-05-13 |
2022-12-22 |
Amgen Inc. |
Vial sleeve assembly
|
|
EP3458988B1
(en)
|
2016-05-16 |
2023-10-18 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
WO2018004842A1
(en)
|
2016-07-01 |
2018-01-04 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
EP3528787B1
(en)
|
2016-10-21 |
2026-01-07 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
|
CN108084262A
(zh)
*
|
2016-11-23 |
2018-05-29 |
复旦大学 |
针对寨卡病毒的全人源单域抗体或抗原结合片段及应用
|
|
KR102014066B1
(ko)
|
2017-01-06 |
2019-10-21 |
에이비엘바이오 주식회사 |
항 α-syn 항체 및 그 용도
|
|
JP2020503976A
(ja)
|
2017-01-17 |
2020-02-06 |
アムジエン・インコーポレーテツド |
注入デバイスならびに関連する使用および組立方法
|
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
|
EP3582829A1
(en)
|
2017-02-17 |
2019-12-25 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
EP3592403B1
(en)
|
2017-03-06 |
2025-08-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
CA3052482A1
(en)
|
2017-03-07 |
2018-09-13 |
Amgen Inc. |
Needle insertion by overpressure
|
|
AU2018230486B2
(en)
|
2017-03-09 |
2023-05-11 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
JP7672196B2
(ja)
|
2017-03-14 |
2025-05-07 |
アムジエン・インコーポレーテツド |
細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
|
|
CN118743804A
(zh)
|
2017-03-28 |
2024-10-08 |
美国安进公司 |
柱塞杆和注射器组件系统以及方法
|
|
AU2018273370B2
(en)
|
2017-05-21 |
2025-04-17 |
Igf Oncology, Llc |
An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
|
|
AU2018280054B2
(en)
|
2017-06-08 |
2023-07-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
CA3066399A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Torque driven drug delivery device
|
|
AU2018288604B2
(en)
|
2017-06-22 |
2023-12-21 |
Amgen Inc. |
Device activation impact/shock reduction
|
|
MA49461A
(fr)
|
2017-06-23 |
2020-04-29 |
Amgen Inc |
Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
|
|
MA49562A
(fr)
|
2017-07-14 |
2020-05-20 |
Amgen Inc |
Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
|
|
US11672733B2
(en)
|
2017-07-21 |
2023-06-13 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
|
US11484648B2
(en)
|
2017-07-25 |
2022-11-01 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
|
JP2020528296A
(ja)
|
2017-07-25 |
2020-09-24 |
アムジエン・インコーポレーテツド |
ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
|
|
WO2019032482A2
(en)
|
2017-08-09 |
2019-02-14 |
Amgen Inc. |
HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
|
|
WO2019036181A1
(en)
|
2017-08-18 |
2019-02-21 |
Amgen Inc. |
BODY INJECTOR WITH STERILE ADHESIVE PATCH
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
WO2019046600A1
(en)
|
2017-08-30 |
2019-03-07 |
Amgen Inc. |
INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
|
|
ES2939292T3
(es)
|
2017-10-04 |
2023-04-20 |
Amgen Inc |
Adaptador de flujo para dispositivo de administración de fármacos
|
|
EP4257164A3
(en)
|
2017-10-06 |
2024-01-17 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
|
EP3694578B1
(en)
|
2017-10-09 |
2025-09-24 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
|
JP2021501198A
(ja)
*
|
2017-10-27 |
2021-01-14 |
トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー |
フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法
|
|
MA50528A
(fr)
|
2017-11-03 |
2020-09-09 |
Amgen Inc |
Systèmes et approches pour stériliser un dispositif d'administration de médicament
|
|
WO2019089178A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
|
US12053618B2
(en)
|
2017-11-06 |
2024-08-06 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
|
IL319987A
(en)
|
2017-11-10 |
2025-06-01 |
Amgen Inc |
Plungers for drug delivery devices
|
|
SG11202003004RA
(en)
|
2017-11-16 |
2020-04-29 |
Amgen Inc |
Door latch mechanism for drug delivery device
|
|
JP7747438B2
(ja)
|
2017-11-16 |
2025-10-01 |
アムジエン・インコーポレーテツド |
失速及び終点検出を有するオートインジェクタ
|
|
BR112020011875A2
(pt)
|
2017-12-14 |
2020-11-24 |
Abl Bio Inc. |
anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
KR20200135781A
(ko)
|
2018-03-26 |
2020-12-03 |
암젠 인크 |
세포 배양에서 생산된 항체의 총 비푸코실화 당형태
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
US12115360B2
(en)
|
2018-07-24 |
2024-10-15 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
US12042645B2
(en)
|
2018-07-24 |
2024-07-23 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
MX2021000749A
(es)
|
2018-07-24 |
2021-03-29 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
EP3829692A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
EP3856283A1
(en)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
AU2019352616B2
(en)
|
2018-10-02 |
2024-10-10 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
US12151089B2
(en)
|
2018-10-05 |
2024-11-26 |
Amgen Inc. |
Drug delivery device having dose indicator
|
|
JP2022504805A
(ja)
|
2018-10-15 |
2022-01-13 |
アムジエン・インコーポレーテツド |
薬物送達デバイスのプラットフォーム式組み立てプロセス
|
|
SG11202103800RA
(en)
|
2018-10-15 |
2021-05-28 |
Amgen Inc |
Drug delivery device having damping mechanism
|
|
AU2019370159B2
(en)
|
2018-11-01 |
2025-05-29 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
US11213620B2
(en)
|
2018-11-01 |
2022-01-04 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
AU2019393487A1
(en)
*
|
2018-12-03 |
2021-06-03 |
Teijin Pharma Limited |
Anti-IGF-I receptor humanized antibody
|
|
JP7590084B2
(ja)
|
2018-12-12 |
2024-11-26 |
ケモセントリックス，インコーポレイティド |
癌治療のためのｃｘｃｒ７阻害剤
|
|
CA3120800A1
(en)
|
2018-12-17 |
2020-06-25 |
Revitope Limited |
Twin immune cell engager
|
|
JP7510952B2
(ja)
|
2019-04-24 |
2024-07-04 |
アムジエン・インコーポレーテツド |
シリンジ滅菌確認アセンブリ及び方法
|
|
WO2020232125A1
(en)
|
2019-05-14 |
2020-11-19 |
Prometheus Biosciences, Inc. |
Tl1a patient selection methods, systems, and devices
|
|
JP7608439B2
(ja)
|
2019-08-23 |
2025-01-06 |
アムジエン・インコーポレーテツド |
構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
|
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
|
CA3177717A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
CR20230204A
(es)
|
2020-10-14 |
2023-10-11 |
Viridian Therapeutics Inc |
Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
|
|
MX2023004364A
(es)
|
2020-10-15 |
2023-05-03 |
Amgen Inc |
Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
|
|
CN116745324A
(zh)
|
2021-01-27 |
2023-09-12 |
信达生物制药(苏州)有限公司 |
针对cd16a的单域抗体及其用途
|
|
AU2022233150A1
(en)
*
|
2021-03-08 |
2023-09-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
MOLECULES THAT BIND TO CD66e POLYPEPTIDES
|
|
CN112794912B
(zh)
*
|
2021-04-14 |
2021-07-06 |
苏州普乐康医药科技有限公司 |
一种抗igf-1r抗体及其应用
|
|
JPWO2022239720A1
(enExample)
|
2021-05-10 |
2022-11-17 |
|
|
|
CA3217207A1
(en)
|
2021-05-21 |
2022-11-24 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
TW202320850A
(zh)
|
2021-08-10 |
2023-06-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
WO2023143484A1
(zh)
*
|
2022-01-29 |
2023-08-03 |
明慧医药（杭州）有限公司 |
一种抗原结合蛋白及其用途
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2024208244A1
(en)
*
|
2023-04-04 |
2024-10-10 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-igf1r antibodies and uses thereof
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025014773A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating chronic thyroid eye disease
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
CN117079823B
(zh)
*
|
2023-10-17 |
2024-01-02 |
北京大学第三医院（北京大学第三临床医学院） |
早期预测选择性胎儿生长受限发病风险筛查的系统和方法
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2026030152A1
(en)
|
2024-07-29 |
2026-02-05 |
Amgen Inc. |
System and method for assessing transferability of a fill recipe
|